NCT06176118
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
See at-risk trials from Vanderbilt University Medical Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: Sep 1, 2026 to May 1, 2027
- Eligibility criteria expanded, about 17 words
- Primary and study completion pushed from Dec 2027 to May 2028
- Secondary endpoints: details revised at 4 of 7 entries
- Notable Primary and study completion dates pushed to Dec 2027
- Start date: May 1, 2026 to Sep 1, 2026
- Notable Start date: Dec 1, 2025 to May 1, 2026
- Primary completion date: Aug 2026 to Dec 2026
- Notable Start date: May 1, 2025 to Dec 1, 2025v6
- Notable Start date: Aug 1, 2024 to May 1, 2025
- Primary completion date: Apr 2026 to Aug 2026
- Study completion date: Jul 2026 to Jul 2027
Show 3 earlier versionsHide 3 earlier versions
- Notable Start date: May 1, 2024 to Aug 1, 2024v4
- Notable Start date: Mar 15, 2024 to May 1, 2024v3
- Notable Start date: Jan 1, 2024 to Mar 15, 2024v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in acetylated SOD2 and LCAD in plasma
Timeframe: baseline and 12-weeks
Secondary (7)
Change in plasma LDL, HDL, triglyceride, free fatty acid concentration measured as a concentration (mg/dL)
Change in plasma acylcarnitine profile measured as a concentration (mg/dL)
Change in meters walked in six-minute walk distance (meters)
Change in Quality of Life as measured by the emPHasis-10
Change in Estimated Right Ventricle (RV) Systolic Pressure, as assessed by echocardiogram results, expressed in mmHg
Show 2 moreShow less
Change in Right Ventricle (RV) Free Wall Longitudinal Strain, as assessed by echocardiogram results, and expressed as percent (%) change in myocardial deformation.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Arms and interventions
Unblinded InterventionExperimental
There is no control group in this study. Only intervention group due to phase of trial and study intentions.
Dietary supplements: 2-HOBA